admin
The Justice Department has quietly nudged the door open for parts of the marijuana business to walk through. A recent DOJ order moved narrow categories of cannabis into Schedule III and kicked off an expedited DEA hearing to consider broader rescheduling. That sounds like a small bureaucratic tweak. In reality, it could ripple through banking, taxes, research and state laws — and conservatives should pay attention, not cheerblindly applaud.
What the DOJ order actually did
The action by Acting Attorney General Todd Blanche immediately reclassified two specific kinds of marijuana products as Schedule III: FDA‑approved marijuana drug products and products handled under qualifying state medical‑marijuana licenses. As Mr. Blanche put it, the change “allows for research on the safety and efficacy of this substance.” DEA Administrator Terry Cole also announced an expedited administrative hearing to examine broader rescheduling. In plain English: the government is trying to create rules for medical cannabis while leaving recreational marijuana in limbo.
Don’t confuse rescheduling with legalization
Let’s be clear. This is not a federal green light for adult‑use weed. Recreational marijuana remains treated like Schedule I material unless and until the DEA changes course in the hearing or Congress acts. State dispensaries are not instantly pharmacies. Questions about who can prescribe what, how pharmacies would dispense it, and how banks should treat cannabis cash remain unanswered. The order starts a process — it does not finish one.
Why industry and accountants are circling the wagons
Some parts of the industry are understandably excited. Schedule III status for qualifying products can ease the path for clinical research. It also creates the possibility of relief from the punishing tax rule known as Section 280E, which has blocked ordinary business deductions for state cannabis sellers. Banks and investors are watching too; better federal classification could make lenders less skittish. Big growers like Glass House Brands point to the change as a sign that the market is maturing — even if their stock has taken some hits along the way.
Conservative concerns and the real risks
Rescheduling through administrative fiat raises legitimate conservative alarms. First, this is regulatory lawmaking without Congress. Second, the practical fixes fans promise — broad banking access and tax relief — depend on follow‑up rules from Treasury, FinCEN and the IRS. That could take months or years, and litigation is likely. Third, federal‑state friction is inevitable. States that tightly regulate medical programs will clash with a patchwork of new federal registration rules. Finally, there are public‑health and enforcement trade‑offs that get little attention in industry press releases.
If you’re for better medical research and smarter policy, you should welcome clarification. But if you prefer decisions made by elected representatives, not by hurried agency memos, you should be wary. The DOJ’s move is a step — not the finish line. Congress should step in, provide clear rules for prescription pathways, banking, and tax relief, and protect community safety. Until then, expect lots of lawyers, lots of filings at the DEA hearing, and a slow slog of rulemaking dressed up as progress. Call it cautious optimism, or call it what it is: bureaucrats rearranging the deck chairs while everyone argues about the captain.
